Researchers at Stanford are mining millions of de-identified patient records using machine learning to determine long-term safety of medical devices.
At a recent talk on campus, Amy Abernethy, an FDA principal deputy commissioner, discussed her career and her work to facilitate clinical advances.
A new Stanford study in children with autism showed the value of teaching parents how to use everyday interactions to motivate their children to speak.
A therapy delayed the onset of Type 1 diabetes in at-risk people by about two years, new results from a clinical trial show.
An antibody against the "don't eat me" signal on cancer cells appears safe and well-tolerated by patients with advanced cancers. A phase 2 trial is planned.
Orthopaedic surgeon Constance Chu has spent her career seeking ways to prevent osteoarthritis from developing after a knee injury.
A Stanford physician argues pregnant women should be appropriately included in clinical research to improve their health and the health of their fetuses.
Sharon Chinthrajah weighs in on a new peanut allergy immunotherapy, speaking to its potential and its role in the future of food allergies therapy.
A novel immunotherapy appears safe for use in patients with non-Hodgkin’s lymphoma. Here, a Northern California man shares his experience in the study.
The anti-inflammatory drug ketoprofen shows promise as effective medical treatment for lymphedema symptoms, small Stanford study finds
A new Stanford-led study catalogs the prevalence and types of deception by volunteers in clinical trials and suggests ways for investigators to root it out.
Most participants in clinical trials believe the benefits of broadly sharing individual data outweigh the risks, a new Stanford study has found.
In a meta-analysis of more than 500 clinical trials, researchers have new conclusions about the efficacy of 21 different antidepressants.
The Project Baseline study is an ambitious endeavor with a potentially transformative payoff. Launched in April after years of designing and planning by Verily, an Alphabet …
Should data from clinical trials be available to all? Or just for certain investigations? Who decides? And how would that work? These, and a host …
Clinical trials, in their current incarnation, are ill-suited for the nimble, personalized precision health era, a a panel of speakers at the Big Data in …